General
Preferred name
ZOLMITRIPTAN
Synonyms
311C90 ()
BW-311C90 ()
Zomig-Zmt ()
311-C-90 ()
Zomig ()
NSC-760383 ()
Cvt-427 ()
P&D ID
PD000525
CAS
139264-17-8
Tags
available
drug
Approved by
FDA
First approval
1997
Drug indication
Migraine
migraine disorder
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Zolmitriptan is triptan type serotonin receptor agonist that is used as an anti-migraine drug. It is selective for the 1B and 1D 5-HT receptor subtypes. Zolmitriptan is the only triptan known to be converted to an active N-desmethyl metabolite which has higher affinity for the 5-HT1D and 5-HT1B receptors than the parent molecule
(GtoPdb)
PRICE
44
DESCRIPTION
Selective EP4 receptor competitive antagonist
(Tocris Bioactive Compound Library)
DESCRIPTION
Potent 5-HT1B/1D/1F agonist
(Tocriscreen Plus)
DESCRIPTION
Zolmitriptan is a member of the triptan class of 5-HT(1B/1D/1F) receptor agonist drugs. It is used for the acute treatment of migraine with or without aura in adults.
(Enamine Bioactive Compounds)
DESCRIPTION
Zolmitriptan (311C90) selectively binds to and activates serotonin (5-HT) 1B receptors expressed in intracranial arteries and 5-HT 1D receptors located on peripheral trigeminal sensory nerve terminals in the meninges and central terminals in brainstem sensory nuclei. Zolmitriptan is a member of the triptan class of agents with anti-migraine properties. Receptor binding results in constriction of cranial vessels, reduction of vessel pulsation and inhibition of nociceptive transmission, thereby providing relief of migraine headaches. Zolmitriptan may also relieve migraine headaches by inhibition of pro-inflammatory neuropeptide release.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
28
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
Tocriscreen Plus
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
43
Molecular Weight
287.16
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
2
cLogP
1.92
TPSA
57.36
Fraction CSP3
0.44
Chiral centers
1.0
Largest ring
6.0
QED
0.88
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
7-TM Receptors
Target
5-HT
5-HT Receptor
HTR1A, HTR1B, HTR1D, HTR1E, HTR1F
Primary Target
5-HT1D Receptors
MOA
Agonist
serotonin receptor agonist
Indication
migraine headache
Therapeutic Class
Antimigraine Agents
Pathway
GPCR/G protein
Neuroscience
Source data
